Market Trends– category –
-
Smoltek and Heraeus Launch Critical 3,000-Hour Durability Test for Ultra-Low Iridium PEM Electrolyzers
Smoltek Nanotech Holding AB Sweden Overview Smoltek Hydrogen and Heraeus Precious Metals are intensifying their joint efforts to develop next-generation, ultra-low iridium Porous Transport Electrodes (PTEs) for Proton Exchange Membrane (... -
UKRI Annual Report: Concretene’s Graphene-Enhanced Concrete Reduces Embodied Carbon by 20-30%, Driving Construction Decarbonization
UKRI UK Overview The UKRI (UK Research and Innovation) annual report highlights Concretene, a Manchester-based nanotechnology firm, which developed an innovative graphene-enhanced concrete admixture. This technology has the potential to ... -
Merck Expands Singapore BioReliance Lab with Asia Pacific’s First Cell Line Characterization and GMP NGS Capabilities
BioPharma APAC Singapore Overview Merck is expanding its Singapore BioReliance lab to strengthen analytical and biosafety testing services in the Asia Pacific region. The expanded facility will offer the first BioReliance Cell Line Chara... -
Rapid Rise of iPSC-Based Therapies: Manufacturing Challenges and FUJIFILM Cellular Dynamics’ Automation Solutions
Contract Pharma International Overview iPSC-based therapies are rapidly advancing as a renewable, standardized source for allogeneic treatments and scalable solutions across various indications. However, manufacturing poses challenges in... -
Building Commercial Readiness in Advanced Therapies: Optimizing Supply Chain, Manufacturing, and Regulatory Strategy is Critical
The Medicine Maker Unknown Overview Achieving commercial readiness for Advanced Therapy Medicinal Products (ATMPs), particularly cell and gene therapy products, is an urgent industry imperative. This requires establishing robust supply c... -
CGT Manufacturers Transform Regulatory Demands into Innovation Drivers: New Strategies for Enhanced Quality and Efficiency
MasterControl USA Overview Cell and gene therapy (CGT) manufacturers are adopting new strategies to leverage stringent regulatory requirements as opportunities for innovation and quality improvement, rather than mere obstacles. Central t... -
CDMO Capacity Crunch Persists in Cell and Gene Therapy Sector: Strategic Partnerships Crucial for Accelerating Innovation
Contract Pharma USA Overview The cell and gene therapy (CGT) sector faces a severe and persistent capacity crunch among Contract Development and Manufacturing Organizations (CDMOs), driven by soaring demand. This bottleneck significantly... -
Autolus Therapeutics Reports 119% YoY Increase in Q2 2026 AUCATZYL® Net Product Sales to $45.7M, Raising Full-Year Guidance and Securing $250M Credit Facility for Extended Runway
Autolus Therapeutics, Inc. (Press Release via GlobeNewswire) USA Overview Autolus Therapeutics announced that its CAR T-cell therapy, AUCATZYL® (obecabtagene autoleucel; obe-cel), generated $45.7 million in net product sales for Q2 2026,... -
Reprogramming the Future: Liv Hospital Details iPSC Therapy’s Transformative Role in Regenerative Medicine
Liv Hospital Turkey Overview Liv Hospital recently published an insightful article on induced pluripotent stem cell (iPSC) therapy, highlighting its profound impact on regenerative medicine, diverse applications, and global clinical prog... -
CRISPR’s Clinical Horizon: Liv Hospital Report Maps 2026 FDA Landscape and Broad Therapeutic Potential
Liv Hospital Turkey Overview Liv Hospital has published a comprehensive review outlining the latest advancements in CRISPR gene-editing technology, emphasizing its revolutionary impact on medical treatments. The report highlights breakth...
